A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Status:
COMPLETED
Trial end date:
2024-10-24
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic patients with overweight in the presence of comorbidities or obesity, in addition to lifestyle intervention.